- PLN66.67m
- PLN78.74m
- PLN47.69m
- 60
- 28
- 45
- 38
Annual income statement for BioMaxima SA, fiscal year end - December 31st, PLN millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | PAS | PAS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 30.5 | 61.6 | 81.1 | 146 | 47.7 |
| Cost of Revenue | |||||
| Gross Profit | 13 | 23.9 | 32.1 | 57.7 | 22.6 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 29.9 | 52.2 | 68.1 | 111 | 47 |
| Operating Profit | 0.629 | 9.4 | 13 | 34.9 | 0.728 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 0.182 | 8.75 | 12.8 | 35.9 | 0.187 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 0.014 | 7.33 | 10.2 | 28.9 | 0.586 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.014 | 7.36 | 10.2 | 28.9 | 0.586 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.014 | 7.36 | 10.2 | 28.9 | 0.586 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.026 | 1.8 | 2.41 | 6.48 | 0.029 |
| Dividends per Share |